Insider · CIK 0001996040
Andrew Moin
director
Files at SABS (SAB Biotherapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2025 | SABS SAB Biotherapeutics, Inc. | MOption exercise Common Stockindirect: See Footnote. | +1,740,000 | $1.75 | $3.0M | 2,198,457 | Oct 1, 2025 |
| Sep 29, 2025 | SABS SAB Biotherapeutics, Inc. | MOption exercise Series B Convertible Preferred Stockderivativeindirect: See Footnote. | -17,400 | - | - | 211,100 | Oct 1, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Series B Convertible Preferred Stockderivativeindirect: See Footnote. | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See Footnote. | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Warrants (right to buy)derivativeindirect: See Footnote. | +114,250 | - | - | 114,250 | Jul 24, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.